{"id":"NCT01485991","sponsor":"Janssen R&D Ireland","briefTitle":"TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy","officialTitle":"Phase III in Partial and Null Responders","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2011-12-06","resultsPosted":"2015-04-10","lastUpdate":"2016-04-26"},"enrollment":771,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"TMC435","otherNames":[]},{"type":"DRUG","name":"TVR","otherNames":[]}],"arms":[{"label":"TMC435/PR","type":"EXPERIMENTAL"},{"label":"TVR/PR","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate the efficacy of TMC435 in combination with peginterferon (PegIFN) + ribavirin (RBV) by means of establishing its non- inferiority compared to an approved regimen of telaprevir + PegIFN + RBV in patients who have previously failed PegIFN.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)","timeFrame":"12 Weeks After the Planned End of Treatment (EOT: Week 48)","effectByArm":[{"arm":"Simeprevir+Placebo+Peginterferon Alfa-2a+Ribavirin","deltaMin":53.6,"sd":null},{"arm":"Telaprevir+Placebo+Peginterferon Alfa-2a+Ribavirin","deltaMin":54.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":137,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Norway","Poland","Portugal","Puerto Rico","Romania","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["25482330"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":379},"commonTop":["Pruritus","Fatigue","Anaemia","Headache","Pyrexia"]}}